Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 65

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 65
---
 rely on third parties for the clinical as well as any future commercial supply of its           
 product candidates and other future product candidates. The development of its current and         
 future product candidates, and the commercialization of any approved products, could be stopped,   
 delayed or made less profitable if any such third party fails to provide Longevity with sufficient 
 clinical or commercial quantities of such product candidates or products, fails to do so           
 at acceptable quality levels or prices or fails to achieve or maintain satisfactory regulatory     
 compliance.                                                                                        |

| ● | Disruptions                                                                                   
 at the FDA and other government agencies and notified bodies caused by funding shortages      
 or global health concerns could hinder their ability to hire, retain or deploy key leadership 
 and other personnel, or otherwise prevent new or modified products from being developed,      
 approved, certified or commercialized in a timely manner or at all, or otherwise prevent      
 those agencies and bodies from performing normal business functions on which the operation    
 of our business may rely, which could negatively impact Longevity’s business.                 |

| ● | Longevity                                                                                  
 may not effectively be able to protect or enforce its intellectual property, which could   
 have a material adverse effect on its business, financial condition, results of operations 
 and prospects.                                                                             |

| ● | If                                                                                             
 Longevity’s trademarks and trade names are not adequately protected, then it may not           
 be able to build name recognition in its markets of interest and its business may be adversely 
 affected.                                                                                      |

| 19 |

<div align='center'>RISK FACTORS</div>

Risks Related to the Business Combination and FutureTech

Unless the context otherwise requires, throughout this subsection, references to “we,” “us,” “our” and “the Company” refer to FutureTech.

FutureTech has no operating history and its results of operations may differ significantly from the unaudited pro forma financial data included in this proxy statement/prospectus.

FutureTech is a blank check company, and it has no operating history or results.

This proxy statement/prospectus includes unaudited pro forma combined financial statements for FutureTech and Longevity. The unaudited pro forma condensed combined balance sheet as of September 30, 2024 combines the historical unaudited condensed balance sheet of FutureTech as of September 30, 2024, the historical unaudited condensed balance sheet of Longevity as of September 30, 2024, the historical unaudited condensed balance sheet of Aegeria as of September 30, 2024 and the historical